NAD is a foundational molecule that plays an essential role in many metabolic and cell regulatory processes—the full implications of which are only now being understood. In addition to its demonstrated benefits for treating addiction, depression, and post-traumatic stress, NAD has been gaining recognition for its role in combating the effects of aging—and for offering powerful possibilities for the treatment of chronic diseases, autoimmune disorders, chronic fatigue, and neurodegenerative diseases like Alzheimer’s and Parkinson’s.
NAD Research, Inc. is the only research foundation devoted exclusively to greater scientific understanding of the clinical applications and benefits of NAD—nicotinamide adenine dinucleotide—a foundational molecule found in every cell in the human body.
We are a nonprofit 501-c-3 scientific research organization with an organizational board and an international scientific advisory board, which oversees and directs current and proposed research projects.
Established in 2017, we have already sponsored half-a-dozen basic and applied research studies on the biochemical workings of NAD (see our Publications section), including:
• A pharmacokinetic study of intravenous NAD in healthy volunteers, conducted in collaboration with the Australasian Research Institute and the University of New South Wales (published in Frontiers in Aging Neuroscience).
• An MRI study, conducted in collaboration with the Center For Magnetic Resonance Research at the University of Minnesota, of NAD levels and ATP production in healthy volunteers.
• A case presentation on a Parkinson’s disease patient conducted in collaboration with the Australasian Research Institute and the University of New South Wales (published in On Journ).
• A retrospective study of the effect of intravenous NAD on self-reported cravings for alcohol and opiates resulting in a poster presentation at the Society For Neuroscience 2015.
• A poster presentation at the Society of Neuroscience on the effect of intravenous NAD on a patient with a Parkinsonian tremor.
• Two published case reports measuring the effects of IV NAD+ with follow-up using nasal spray/sublingual NAD+ protocols on symptoms associated with Parkinson’s Disease (Gadol, et al., 2019; Rutherford, et al., 2020)
• Poster/oral presentations at the Mississippi Academy of Sciences (Thompson, et al., 2022) and Society for Neuoscience (White, et al., 2022) using sphenocath NAD for treatment of migraine headache pain
Although our primary investigative focus is intravenous NAD administration, we are also exploring the effectiveness of other administration strategies for NAD, including a trans-sphenopalatine ganglia (trans-nasal) delivery system.
One such case study, Intranasal Administration of Nicotinamide Adenine Dinucleotide Alleviates Headaches Associated with Migraine Pain: A Case Report, was presented at the Mississippi Academy of Sciences in March 2022.
Another, Intranasal administration of nicotinamide adenine dinucleotide alleviates headaches associated with migraine headache pain and reduces adverse effects of anxiety disorders: A case report will be presented at the Society for Neuroscience, San Diego, CA, in November 2022.
Our research is conducted at our treatment facility, Springfield Wellness Center, in Springfield, Louisiana, and at research laboratories around the world led by our collaborators and Advisory Board members.
In addition, we also host periodic international gatherings of researchers and clinicians at the NAD+ Brain Restoration Summit. Please see the speakers and schedule for an idea of the breadth and depth of NAD basic and applied research topics presented.
You can help us advance medical understanding of this essential molecule. Your donation to NAD Research, Inc., is fully tax-deductible to the extent allowed by law. Give through our fast, secure online payment portal, or make your check payable to NAD Research Inc., and mail to 32872 Cullom Road, Springfield, LA 70464.